Fusen Pharmaceutical Company Limited (stock code: 01652) announced its monthly return for January 2026, confirming that its authorised share capital remains at 2,000,000,000 ordinary shares, with a par value of HKD 0.01 per share, totaling HKD 20,000,000.

The company also reported no change in the issued share capital, maintaining 739,301,000 issued ordinary shares with zero treasury shares. The public float requirement has been met, complying with the prescribed threshold of 25%.

In relation to share options under the scheme adopted on 14 June 2018 and granted on 19 July 2019, 16,000,000 share options remain outstanding at an exercise price of HKD 3.098 per share. No new shares were issued, and no treasury shares were transferred during the month.